Suppr超能文献

[心脏再同步治疗候选人的选择及其反应的预测。]

[Selection of candidates for cardiac resynchronisation therapy and prediction of their response.].

作者信息

Agosti S, Casalino L, Bertero G, Morelloni S, Bezante G P, Barsotti A, Brunelli C

机构信息

Dipartimento di Cardiologia, Scuola di Medicina, Università di Genova, Italia.

出版信息

Clin Ter. 2010;161(2):143-8.

Abstract

AIMS

Cardiac resynchronization therapy is currently used in selected patients with end-stage heart failure. However, 30% of patients do not respond to CRT. The aim of our study was to find echocardiographic (TDI), electrocardiographic (QRS interval and electric distance between right and left catheter), clinical (6MW test) or autonomical (HRV) parameters able to predict responsiveness to CRT.

MATERIALS AND METHODS

47 patients (mean age 74+/-10 years) with end-stage heart failure, symptomatic, with left ventricular (LV) ejection fraction less than 35% and QRS 120 ms, underwent CRT.

RESULTS

At thirteen months follow up, all clinical and echocardiographic parameters significantly improves (EF p<0.001; LVED volume p<0.001; 6MWT p<0.001; max delay TDI p<0.001; HRV p<0.05; Right-left distance p<0.05). A positive response was documented in 31/47 (67.4%) patients who presented an increase in LVEF > or = 5 units. There was a significant difference of LVED diameter (p<0.05) and HRV (p<0.05) between responders and non responders. Receiver-operating curve analysis showed that a positive response to CRT may be predicted in patients with LVED diameter <67 mm (with a sensitivity of 77% and a specificity of 88%).

CONCLUSIONS

Our results confirm the clinical improvement obtained by CRT in end-stage heart failure patients as well as the limited value of QRS duration and intraventricular dyssynchrony as predictor of clinical recovery after CRT. While a most-advanced clinical stage of disease (HRV) without an advance left ventricular remodeling (LVED diameter) demonstrated to predict response to CRT, with sensitivity of 77% and specificity of 88%.

摘要

目的

心脏再同步治疗目前用于特定的终末期心力衰竭患者。然而,30%的患者对心脏再同步治疗无反应。我们研究的目的是寻找能够预测对心脏再同步治疗反应性的超声心动图(组织多普勒成像)、心电图(QRS间期以及左右导管之间的电距离)、临床(6分钟步行试验)或自主神经(心率变异性)参数。

材料与方法

47例终末期心力衰竭患者(平均年龄74±10岁),有症状,左心室射血分数小于35%且QRS时限≥120毫秒,接受了心脏再同步治疗。

结果

在13个月的随访中,所有临床和超声心动图参数均显著改善(射血分数p<0.001;左心室舒张末期容积p<0.001;6分钟步行试验p<0.001;组织多普勒成像最大延迟p<0.001;心率变异性p<0.05;左右距离p<0.05)。31/47(67.4%)例左心室射血分数增加≥5个单位的患者有阳性反应。反应者与无反应者之间左心室舒张末期直径(p<0.05)和心率变异性(p<0.05)存在显著差异。受试者操作曲线分析表明,左心室舒张末期直径<67毫米的患者可能对心脏再同步治疗有阳性反应(敏感性为77%,特异性为88%)。

结论

我们的结果证实了心脏再同步治疗在终末期心力衰竭患者中取得的临床改善,以及QRS时限和心室内不同步作为心脏再同步治疗后临床恢复预测指标的有限价值。虽然疾病的最晚期临床阶段(心率变异性)且无左心室提前重构(左心室舒张末期直径)被证明可预测对心脏再同步治疗的反应,敏感性为77%,特异性为88%。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验